Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis
暂无分享,去创建一个
S. Jeha | R. Handgretinger | J. Bourquin | G. Zugmaier | P. Bader | Christiane Chen-Santel | B. Brethon | P. Schlegel | C. Rössig | Noemi Mergen | F. Locatelli | W. Kormany | Puneeth Viswagnachar
[1] O. Hrusak,et al. Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. , 2021, JAMA.
[2] M. Loh,et al. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. , 2021, JAMA.
[3] Michael L. Wang,et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study , 2020, The Lancet.
[4] F. Locatelli,et al. Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study , 2020, Blood Cancer Journal.
[5] J. Hernández-Rivas,et al. Integrated Genomic Analysis of Chromosomal Alterations and Mutations in B-Cell Acute Lymphoblastic Leukemia Reveals Distinct Genetic Profiles at Relapse , 2020, Diagnostics.
[6] S. Hunger,et al. How I Treat Relapsed Acute Lymphoblastic Leukemia in the Pediatric Population. , 2020, Blood.
[7] Michael L. Wang,et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. , 2020, The New England journal of medicine.
[8] S. Holstein,et al. CAR T‐Cell Therapy in Hematologic Malignancies: A Voyage in Progress , 2020, Clinical pharmacology and therapeutics.
[9] S. Jagannath,et al. Anti‐BCMA CAR T‐Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma , 2019, The New England journal of medicine.
[10] M. Schrappe,et al. Durable remissions in TCF3-HLF positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation , 2019, Haematologica.
[11] E. Lanino,et al. Unrelated donor vs HLA-haploidentical α/β T-cell- and B-cell-depleted HSCT in children with acute leukemia. , 2018, Blood.
[12] Ke Liu,et al. FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia , 2018, Clinical Cancer Research.
[13] H. Dombret,et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. , 2018, Blood.
[14] G. Basso,et al. Pre‐ and post‐transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia , 2018, British journal of haematology.
[15] K. Davis,et al. Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia , 2018, The New England journal of medicine.
[16] R. Levy,et al. Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.
[17] W. Klapper,et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia , 2017, The New England journal of medicine.
[18] A. Borkhardt,et al. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] C. Mullighan,et al. Acute Lymphoblastic Leukemia in Children. , 2015, The New England journal of medicine.
[20] J. Downing,et al. Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] S. Rutella,et al. How I treat relapsed childhood acute lymphoblastic leukemia. , 2012, Blood.
[22] M. Labopin,et al. Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP–EBMT analysis , 2012, Leukemia.
[23] M. Schrappe,et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] M. Loh,et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] H. Sather,et al. Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children's Oncology Group study CCG-1952. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.